BioLineRX
BLRX
14 hedge funds and large institutions have $136K invested in BioLineRX in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
30% more capital invested
Capital invested by funds: $104K → $136K (+$31.3K)
0.45% more ownership
Funds ownership: 0.65% → 1.1% (+0.45%)
0% more funds holding
Funds holding: 14 → 14 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
3% less call options, than puts
Call options by funds: $33K | Put options by funds: $34K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$92K |
| 2 |
Citigroup
New York
|
+$7.04K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$5.18K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$978 |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$86 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$20.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$15.3K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$147 |
| 4 |
SS
SBI Securities
Tokyo,
Japan
|
-$8 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $104K | +$92K | +26,631 | +266% |
|
|
2
RhumbLine Advisers
Boston,
Massachusetts
| $9.55K | +$978 | +283 | +9% |
|
|
3
Citigroup
New York
| $5.81K | +$7.04K | +2,038 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $5.4K | -$15.3K | -4,436 | -69% |
|
5
Wells Fargo
San Francisco,
California
| $4.85K | – | – | – |
|
|
6
BNP Paribas Financial Markets
Paris,
France
| $4.16K | +$5.18K | +1,500 | New |
|
|
NRG
7
Nemes Rush Group
Novi,
Michigan
| $693 | – | – | – |
|
|
NA
8
NewEdge Advisors
New Orleans,
Louisiana
| $296 | – | – | – |
|
|
9
Morgan Stanley
New York
| $277 | -$20.2K | -5,853 | -98% |
|
|
10
Osaic Holdings
Scottsdale,
Arizona
| $71 | +$86 | +25 | +2,500% |
|
11
Rockefeller Capital Management
New York
| $33 | – | – | – |
|
12
Bank of America
Charlotte,
North Carolina
| $28 | +$28 | +8 | +400% |
|
|
DB
13
Danske Bank
Copenhagen K,
Denmark
| $6 | – | – | – |
|
|
TRCT
14
Tower Research Capital (TRC)
New York
| – | -$147 | -39 | Closed |
|
|
SS
15
SBI Securities
Tokyo,
Japan
| – | -$8 | -2 | Closed |
|
|
BCV
16
Banque Cantonale Vaudoise
Lausanne,
Switzerland
| – | +$3 | +1 | New |
|
BLRX Hedge Fund Activity: Q4 2025 in Review
14 of the 8,245 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q4 2025, worth a combined $136K — up 30% from $104K a quarter earlier.
Fund positioning in BLRX was balanced in Q4 2025: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $92K. The largest seller was Morgan Stanley, cutting an estimated $20.2K.
- 14 institutional investors held BioLineRX (BLRX) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $136K of BioLineRX stock for Q4 2025, up 30% quarter-over-quarter.
- 3 funds opened new BioLineRX positions in Q4 2025 and 3 closed out, a net change of 0 holders.
- The largest BioLineRX buyer in Q4 2025 was Citadel Advisors, an estimated $92K added.
- The largest BioLineRX seller in Q4 2025 was Morgan Stanley, an estimated $20.2K sold.
Based on aggregated 13F filings for Q4 2025.